1. Home
  2. JFIN vs EOLS Comparison

JFIN vs EOLS Comparison

Compare JFIN & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$6.25

Market Cap

330.9M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$5.68

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
EOLS
Founded
2011
2012
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.9M
304.0M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
JFIN
EOLS
Price
$6.25
$5.68
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.40
AVG Volume (30 Days)
57.6K
1.1M
Earning Date
01-01-0001
05-21-2026
Dividend Yield
13.03%
N/A
EPS Growth
N/A
1.23
EPS
N/A
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
N/A
$14.41
Revenue Next Year
N/A
$16.96
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
11.61
52 Week Low
$5.73
$4.09
52 Week High
$18.70
$13.81

Technical Indicators

Market Signals
Indicator
JFIN
EOLS
Relative Strength Index (RSI) 43.96 68.56
Support Level $5.81 $4.74
Resistance Level $6.70 $7.29
Average True Range (ATR) 0.30 0.28
MACD -0.01 0.18
Stochastic Oscillator 43.75 75.58

Price Performance

Historical Comparison
JFIN
EOLS

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: